
    
        <!DOCTYPE html>
        <html lang="hu-HU" data-website-id="1" data-oe-company-name="HBS Medical">
            
<!-- Mirrored from hbs.hu/slides/slide/intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:04:10 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
                <meta charset="utf-8"/>
                <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
                <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no"/>

                <title>Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections- Results from a multicentre survey.cuaj-9-10-e721 | HBS</title>
                <link type="image/x-icon" rel="shortcut icon" href="../../web/image/website/1/favicon/index.html"/>

                <script type="text/javascript">
                    var odoo = {
                        csrf_token: "f2e9a41588799d043a772b21ddc3189150ea199fo",
                    };
                </script>

                
            <meta name="generator" content="Odoo"/>

            
            
            
            
            
            
                
                
                
                    
                        <meta property="og:type" content="website"/>
                    
                        <meta property="og:title" content="Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections- Results from a multicentre survey.cuaj-9-10-e721"/>
                    
                        <meta property="og:site_name" content="HBS Medical"/>
                    
                        <meta property="og:url" content="https://hbs.hu/slides/slide/intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31"/>
                    
                        <meta property="og:image" content="https://hbs.hu/web/image/slide.slide/31/image_thumb"/>
                    
                        <meta property="og:description"/>
                    
                
                
                
                    
                        <meta name="twitter:card" content="summary_large_image"/>
                    
                        <meta name="twitter:title" content="Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections- Results from a multicentre survey.cuaj-9-10-e721"/>
                    
                        <meta name="twitter:image" content="https://hbs.hu/web/image/slide.slide/31/image_thumb"/>
                    
                        <meta name="twitter:description"/>
                    
                
            

            
            
                
                    <link rel="alternate" hreflang="hu" href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html"/>
                
            

            <script type="text/javascript">
                odoo.session_info = {
                    is_admin: false,
                    is_system: false,
                    is_frontend: true,
                    translationURL: '/website/translations',
                    is_website_user: true,
                    user_id: 4
                };
                
            </script>

            <link type="text/css" rel="stylesheet" href="../../web/content/521-3ab7b2c/1/web.assets_common.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/599-e81acc7/1/web.assets_frontend.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/600-e81acc7/1/web.assets_frontend.1.css"/>
            
            
            

            <script type="text/javascript" src="../../web/content/524-3ab7b2c/1/web.assets_common.js"></script>
            <script type="text/javascript" src="../../web/content/603-e81acc7/1/web.assets_frontend.js"></script>
            
            
            
        
            </head>
            <body>
                
            
        
            
        
        
            
                
                    
                
                
            
        
        
    
    

            
            
        
    
            
          
        <link rel="stylesheet" type="text/css" href="../../sh_cookie_notice/static/src/css/cookieconsent.min.css"/>
        <script type="text/javascript" src="../../sh_cookie_notice/static/src/js/cookieconsent.min.js"></script>
        

	
	<script type="text/javascript"> 

	 window.addEventListener("load", function(){
 
	var sh_msg = String("Az HBS weboldala sütiket használ a weboldal működtetése, használatának megkönnyítése, a weboldalon végzett tevékenység nyomon követése és releváns ajánlatok megjelenítése érdekében.");
	var sh_esc_msg = encodeURIComponent(sh_msg);
	sh_esc_msg = decodeURIComponent(sh_esc_msg); 
	
  	window.cookieconsent.initialise({
	  "palette": {
	    "popup": {
	      "background": "#000" 
	    },
	    "button": {
	      "background": "#f1d600"
	    }
	  },
	  
	  	  "position": "top",
	  
	
	  
	  "content": {
	    "message": sh_esc_msg,
	    "dismiss": "Elfogadom",
	    "allow": "allow",
	    "link": "Adatvédelmi tájékoztató",
	    "href": "/adatkezelesi-tajekoztato"
	  }
	})});
    </script>
 
   
    <div id="wrapwrap" class="   ">
                <header class=" o_affix_enabled">
                    <nav class="navbar navbar-expand-md navbar-light bg-light">
                        <div class="container">
                            <a href="../../index.html" class="navbar-brand logo">
            <span role="img" aria-label="Logo of HBS Medical" title="HBS Medical"><img src="../../web/image/res.company/1/logo66cf.png?unique=866a03a" class="img img-fluid"/></span>
        </a>
    <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#top_menu_collapse">
                                <span class="navbar-toggler-icon"></span>
                            </button>
                            <div class="collapse navbar-collapse" id="top_menu_collapse">
                                <ul class="nav navbar-nav ml-auto text-right o_menu_loading" id="top_menu">
                                    
        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../index.html" class="nav-link ">
            <span>HBS Medical</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="https://covid-19.hbs.hu" class="nav-link " target="_blank">
            <span>COVID-19</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../blog/hirek-esemenyek-1.html" class="nav-link ">
            <span>Hírek</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../aboutus.html" class="nav-link ">
            <span>Kapcsolat</span>
        </a>
    </li>
    

        
    
                                    
                                </ul>
                            </div>
                        </div>
                    </nav>
                </header>
                <main>
                    
        
        <div class="container mt16">
            <div class="row">
                <div class="col-xl-8 col-lg-8 col-md-12 col-12">
                    

                    <div>
                            
                        <div class="embed-responsive embed-responsive-4by3 embed-responsive-item mb8">
                            <iframe src="../embed/312679.html?page=1" class="o_wslides_iframe_viewer" allowFullScreen="true" height="315" width="420" frameborder="0"></iframe>
                        </div>
                        
                        <div class="row">
                            <h4 class="col-lg-6">Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections- Results from a multicentre survey.cuaj-9-10-e721</h4>
                            <div class="col-lg-6">
                                <div clas="row">
                                    
                                </div>
                            </div>
                        </div>
                        <div class="row">
                            <div class="col-md-8 col-12">
                                <div class="float-left">
                                    <a href="../nyilvanos-anyagok-1.html" title="Channel Nyilvános anyagok" aria-label="Channel Nyilvános anyagok">
                                        <i class="fa fa-circle-o fa-5x" style="color: #875A7B;font-weight: bold;"></i>
                                    </a>
                                </div>
                                <div style="margin-left: 80px">
                                    <p>
                                        <a href="../nyilvanos-anyagok-1.html">Nyilvános anyagok</a>
                                        
                                            <span> / </span>
                                            <a href="../nyilvanos-anyagok-1/category/szakirodalmi-cikkek-3.html">Szakirodalmi cikkek</a>
                                        
                                    </p>
                                    <div>
                                        
        <div class="input-group js_follow" data-id="1" data-object="slide.channel" data-follow="off">
            <input type="email" name="email" class="js_follow_email form-control" placeholder="emailje..."/>
            <div class="input-group-append">
                <button href="#" class="btn btn-secondary js_unfollow_btn">Leiratkozás</button>
                <button href="#" class="btn btn-primary js_follow_btn">Feliratkozás</button>
            </div>
        </div>
    
                                    </div>
                                </div>
                            </div>
                            <div class="col-md-4 d-none d-md-block">
                                <div class="text-right">
                                    <b class="h3 text-muted">1387</b> <span class="text-muted small">views</span>
                                </div>
                                
                                <div class="progress mb0" style="height: 2px;">
                                    <div class="progress-bar" role="progressbar" aria-valuenow="0" aria-valuemin="0" aria-valuemax="100" style="width: 0%;">
                                        <span class="sr-only">0 Likes</span>
                                    </div>
                                </div>
                                <div class="text-muted mt4">
                                    <div class="float-right mb16 text-right">
                                        <span class="oe_slide_js_like" data-href="/slides/slide/like" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="31">
                                            <i class="fa fa-thumbs-up fa-1x" role="img" aria-label="Likes" title="Likes"></i>
                                            0
                                        </span>
                                        <span class="oe_slide_js_unlike" data-href="/slides/slide/dislike" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="31">
                                            <i class="fa fa-thumbs-down fa-1x" role="img" aria-label="Dislikes" title="Dislikes"></i>
                                            0
                                        </span>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="mt8 mb32">
                            <ul class="nav nav-tabs" role="tablist">
                                <li class="nav-item">
                                    <a href="#about" aria-controls="about" role="tab" data-toggle="tab" class="nav-link active">
                                        <i class="fa fa-home"></i> About
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#share" aria-controls="share" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-share-alt"></i> Share
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#discuss" aria-controls="discuss" role="tab" data-toggle="tab" class="nav-link">
                                        <i class="fa fa-comments-o"></i> Comments
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#transcript" aria-controls="transcript" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-align-justify"></i> Transcript
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#statistic" aria-controls="statistic" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-bar-chart"></i> Statistics
                                    </a>
                                </li>
                            </ul>
                            <div class="tab-content" style="padding: 20px 5px 5px 5px; word-wrap: break-word;">
                                <div role="tabpanel" id="about" class="tab-pane fade active in">
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="share">
                                    
    <h4 class="mt0">Share on Social Networks</h4>
    
    <div>
        <a class="o_slides_social_share" social-key="facebook" aria-label="Share on Facebook" title="Share on Facebook" href="https://www.facebook.com/sharer/sharer.php?u=https://hbs.hu/r/1ZB"><i class="fa fa-facebook-square fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="twitter" aria-label="Share on Twitter" title="Share on Twitter" href="https://twitter.com/intent/tweet?text=Intravesical%20treatment%20with%20highly-concentrated%20hyaluronic%20acid%20and%20chondroitin%20sulphate%20in%20patients%20with%20recurrent%20urinary%20tract%20infections-%20Results%20from%20a%20multicentre%20survey.cuaj-9-10-e721&amp;url=https://hbs.hu/r/1ZB"><i class="fa fa-twitter fa-2x"></i></a>
        <a social-key="linkedin" class="o_slides_social_share" aria-label="Share on LinkedIn" title="Share on LinkedIn" href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://hbs.hu/r/1ZB&amp;title=Intravesical%20treatment%20with%20highly-concentrated%20hyaluronic%20acid%20and%20chondroitin%20sulphate%20in%20patients%20with%20recurrent%20urinary%20tract%20infections-%20Results%20from%20a%20multicentre%20survey.cuaj-9-10-e721&amp;"><i class="fa fa-linkedin fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="gplus" aria-label="Share on Google Plus" title="Share on Google Plus" href="https://plus.google.com/share?url=https://hbs.hu/r/1ZB"><i class="fa fa-google-plus-square fa-2x"></i></a>
    </div>

    <h4 class="mt-3">Share Link</h4>
    <input type="text" class="form-control" readonly="readonly" onClick="this.select();" value="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html"/>
    <span class="form-text">Use permanent link to share in social media</span>

                                    
    <h4 class="mt-3">Share with a friend</h4>
    
    
        <p>Please <a href="../../web/login.html?redirect=https://hbs.hu/slides/slide/intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31"> login </a> to send this document by email!</p>
    

                                    
                                        
    <div class="oe_slide_js_embed_code_widget">
        <h4 class="mt0">Embed in your website</h4>
        <div class="form-group">
            <textarea class="form-control slide_embed_code" readonly="readonly" onClick="this.select();">&lt;iframe src=&quot;https://hbs.hu/slides/embed/31?page=1&quot; class=&quot;o_wslides_iframe_viewer&quot; allowFullScreen=&quot;true&quot; height=&quot;315&quot; width=&quot;420&quot; frameborder=&quot;0&quot;&gt;&lt;/iframe&gt;</textarea>
        </div>
        <div class="form-group">
            <div class="form-text col-xl-3 col-lg-3 col-md-6 col-6">Select page to start with</div>
            <div class="input-group col-xl-3 col-lg-3 col-md-6 col-6">
                <input type="number" value="1" class="form-control"/>
            </div>
        </div>
    </div>

                                    
                                </div>
                                
                                <div role="tabpanel" id="discuss" class="tab-pane fade">
                                    
        <div id="discussion" class="d-print-none o_portal_chatter o_not_editable p-0" data-res_model="slide.slide" data-res_id="31" data-pager_step="10" data-allow_composer="1">
        </div>
    
                                </div>
                                <div role="tabpanel" class="tab-pane fade oe_slides_transcript" id="transcript">
                                    
                                        
                                            <p>4. CUAJ • September-October 2014 • Volume 8, Issues 9-10 E724 c icione et al. Fig. 1.  Kaplan-Meier plotting of time to recurrence of infection. Fig. 2.  Pelvic pain and urinary/frequency symptoms, total score and SF-36 quality of life score during patient follow-up. </p>
                                        
                                            <p>2. CUAJ • September-October 2014 • Volume 8, Issues 9-10 E722 c icione et al. number of preclinical and clinical studies advocating a sig - nificant role of  GAGs disorders in the pathogenesis of many  chronic bladder diseases, such as bacterial recurrent UTIs,  interstitial cystitis, overactive bladder, and bladder cancer. 9   Parsons and colleagues, 10  in an animal   study, identified a  GAGs layer covering the superficial layer of urothelium as  responsible for the antibacterial defense mechanism of the  bladder. A domino-like theory was postulated as cause of  the chronic course of bladder disease, where GAGs layer  loss that fails to heal was the first step leading to direct  exposure of epithelial cells to urine components, facilitating  bacterial adherence and infection 9,11  and chronic bladder  inflammation. 12 Considering the loss of urothelium GAGs layer as a key  factor promoting recurrent UTIs, a therapy aimed at restor - ing GAGs layer, based on the combination of hyaluronic  acid (HA) and chondroitin sulphate (CS), was conceived and  recently suggested as an option to prevent recurrent cystitis. To date, few clinical studies support the benefit of HA and  CS in this setting. 13-17  Although a positive effect was reported,  a small sample was considered the main limitation of the  studies supporting the use of GAGs to prevent UTI. More  robust analyses of larger samples are required to corroborate  positive findings from early series. 14-17 This study was initiated as a collaborative effort to pro - vide a review of clinical outcomes from centres pioneering  the intravesical instillation of Ialuril (IBSA International) (HA  1.6% plus CS 2%) for prophylaxis of recurrent urinary tract  infections (UTIs) in female patients. Methods  Study design  This was a retrospective cohort multicenter study involving  7 European centers. The study was approved by the Magna  Graecia University institutional review board and a data- sharing agreement was obtained from each participating site. Clinical data and outcomes of patients who had under - gone to Ialuril instillations between January 2010 and March  2012 were collected and gathered into a dedicated data - sheet. Inclusion and exclusion criteria  Eligible patients were women with a documented history  of bacterial recurrent UTIs, defined as at least 3 episodes  of uncomplicated UTIs with the isolation of &gt;10 3  CFU/mL  of an identified pathogen with clinical symptoms in the last  12 months. 1 Patients were excluded if they had &lt;3 uncomplicated  UTIs in the previous year, significant (&gt;50   mL) post-voidal  residual urine, neurologic bladder disease, known bladder  neoplasia, urinary stone or abnormality of the urinary tract,  renal insufficiency, diabetes mellitus, current corticosteroid  use, current immunosuppressive disease, use of spermicides  or intrauterine devices, current pregnancy or if they were  on an antibiotic prophylaxis regimen.  Treatment protocol  Treatment protocol consisted of intravesical instillations of  50   mL Ialuril (HA 1.6% and CS 2%), weekly for 4 weeks  (induction phase), and then monthly for 5 months (mainte - nance phase). Three days before each intravesical instilla - tion, urinalysis and urine culture were performed. In case of  asymptomatic bacteruria or UTI, the treatment was delayed  and an antibiotic treatment was administered just in UTI  cases.   Assessment  The following variables were collected: demographic data,  including age, body mass index, menopausal status, and his - tory of constipation (defined as having a bowel movement  fewer than three times per week); disease-related features,  including UTI frequency, UTI recurrence time over the last  year, previous pathogens involved in recurrent UTIs; history  of prescribed antibiotics; cystoscopic findings; and uroflow - metry findings. Cystoscopy was performed without antibiotic  prophylaxis.   After enrollment, patients were monitored at 1 month  (V1) and then every 6 months up to 24 months (V2, V3,  V4, V5). At every visit patients completed the Pelvic Pain  and Urinary/Frequency (PUF) patient symptom scale 18  and  the quality of life (QoL) Short Form (SF)-36 questionnaires 19   to assess symptom score and quality of life, respectively.  Moreover,  urinalysis  and  urine  culture  were  performed  before each bladder instillation and at each follow-up visit,  both in healthy and symptomatic patients, through a clean- catch midstream urine sample, to appraise UTI episodes,  as defined by EAU guidelines. 1  We also recorded other  therapies given to patients during treatment or during the  follow-up period. The following treatment outcomes were analyzed:   treat - ment-related side effects; pain/discomfort at weekly and  monthly instillations end (V1 and V2); treatment efficacy  assessed by calculating any reduction of UTI episodes per  patient per year, length of time to UTI recurrence (defined  as the time elapsed between the first instillation and the  first recurring UTI), and by impact of therapy on QoL and  urinary symptoms. </p>
                                        
                                            <p>7. CUAJ • September-October 2014 • Volume 8, Issues 9-10 E727 i ntravesical  gag s treatment in patients with recurrent UT i s 24.   Nicolle LE. Complicated urinary tract infection in adults.  Can J Infect Dis Med Microbiol  2005;16:349-60. 25.   Tay H, Parsons CL, Stein PC. Electrophysiologic monitoring of the effects of soluble virulence factors  produced by Escherichia coli infection in urine.  Urology  1996;48:389-92. http://dx.doi.org/10.1016/ S0090-4295(96)00209-9 26.   Aslan G, Esen N, Esen AA, et al. Recovery period of the bladder after exposure to soluble virulence factor  produced by Escherichia coli.  Eur Urol  2001;40:446-50. http://dx.doi.org/10.1159/000049814 27.   Kamhi E, Joo EJ, Dordick JS, et al. Glycosaminoglycans in infectious disease.  Biol Rev Camb Philos Soc   2013;88:928-43. http://dx.doi.org/10.1111/brv.12034 28.   Rouschop KM, Sylva M, Teske GJ, et al. Urothelial CD44 facilitates Escherichia coli infection of the murine  urinary tract.  J Immunol  2006;177:7225-32. http://dx.doi.org/10.4049/jimmunol.177.10.7225 29.   Foxman B. The epidemiology of urinary tract infection.  Nat Rev Urol  2010;7:653-60. http://dx.doi. org/10.1038/nrurol.2010.190 30.   Scott RA, Panitch A. Glycosaminoglycans in biomedicine.  Wiley Interdiscip Rev Nanomed Nanobiotechnol  2013;5:388-98.  http://dx.doi.org/10.1002/wnan.1223 Correspondence:  Dr. Antonio Cicione, Magna Graecia University, Catanzaro, Italy;  <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="b1d0d2d8d2d8dedfd4f1ddd8d3d4c3de9fd8c5">[email&#160;protected]</a> ;  <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="e3808a808a8c8d86a3968d8a8099cd8a97">[email&#160;protected]</a> </p>
                                        
                                            <p>5. CUAJ • September-October 2014 • Volume 8, Issues 9-10 E725 Discussion  There are now numerous data showing that bladder uro - thelium is a complex active sensorial layer able to release  several chemical mediators influencing bladder function. 20   In this context, GAGs would play an important role shaping  a protective impermeable layer over whole urothelium, thus  inhibiting direct contact between transitional epithelium and  urine solutes or microorganisms. 21 In particular, E. Coli is the most frequent uropathogen  associated with 75% to 90% and about 60% of the cases  of uncomplicated 22,23  and complicated UTIs, 24  respectively.  Current evidence suggests that E. coli-infected urine contains  soluble factors that can damage the GAGs layer. 25  Moreover,  in individuals with an impaired bladder mucosa, E. Coli  colonization and growth is even easier, because the repair - ing process has been not completed. 26  Of many others, these  studies may lead to consider GAGs layer as a likely target  for medications against bacterial UTIs, and for other chronic  bladder diseases as well.  Current findings provide clinical evidence that GAGs  replacement therapy can be used to prevent urinary infec - tion in women complaining of recurrent UTIs. 14-17  Indeed  we observed both a significant reduction of rate of recurrent  UTIs per year and an increased time-to-recurrence, along  with an improvement of urinary symptoms. These improve - ments persisted for 12 months after the end of treatment,  with a subsequent worsening. Furthermore, the regression  analysis confirmed previously recognized risk factors for UTI  episodes thus indicating women over 50 and those with  &gt;4 UTI episodes per year at higher risk, and thus likely to  receive the highest benefit from a prophylactic intravesical  GAGs therapy. Few prospective randomized controlled trials showed that  intravesical GAGs therapy could be considered a non-anti - biotic alternative therapy for women with recurrent UTIs. 14-17   Considering the largest cohort of patients ever reported, our  findings confirm the results of 3 previously published reports  supporting the role of GAGs layer repair as a valid treatment  option for bacterial recurrent UTIs.  The “restoring mechanism” was hypothesized as the main  prophylactic mechanism of GAGs; 9,14-16  however, a further  “antagonist mechanism” of GAGs therapy can also explain  the  reduction  of  UTI  episodes.  Kamhi  and  colleagues 27   recently highlighted that GAGs therapy represents the first  i ntravesical  gag s treatment in patients with recurrent UT i s Table 2. Therapy outcomes during follow-up Follow-up clinic visit V1 at 1 month V2 at 6 months V3 at 12 months V4 at 18 months V5 at 24 months p  value* No. evaluated patients 157 157 157 71 41 n/a Reported UTIa episodes 2 36 69 130 139 n/a Patients with UTIa, no. (%) 2 (1%) 30 (22.3%) 22 (18.1%) 22 (30.9%) 15 (36.5%) 0.001 Mean rate of UTIa  episodes/ patient 0.01 (0.11) 0.23 (0.42)  0.44 (0.50)  1.83 (1.02)  3.39 (1.79) 0.01 Pathogen involved: E. Coli/ others 2/0 21/9 19/3 18/4 13/2 0.001 Antibiotic regimen prescribed  (quinolones/others) 2/0 24/6 18/4 14/4 14/1 0.001 Total PUF score 16.7 (3.87) 15.3 (4.95) 14.4 (4.61) 15.4 (3.61) 16.5 (3.91) 0.01 Symptom score 11.2 (2.89) 10.17 3.08) 9.6 (3.13) 11.4 (4.32) 12.6 (4.18) 0.01 SF-36 score 65.6 (9.1) 70.39 (8.01) 77.92 (5.89) 69.52 (6.19) 67.5 (4.71) 0.01 Adverse events n/a n/a n/a Patients, no. (%) 2 (1%) 8 (5%) Mean VAS score Minimal (VAS 1-3) Moderate (VAS 4-7)  4.5 (0.7) 4.2 (0.5) 0.87 Severe (8-10) Length, days 2.5 (0.5) 2.2 (0.3) 0.50 V: visit; UTI: urinary tract infection; PUF: pelvic pain and urinary/frequency patient symptom scale; VAS: visual analogue scale; n/a: not applicable. aUTI defined as isolation of  ≥ 103 colony- forming units per milliliter of an identified pathogen in a patient with urinary symptoms. Data of continuous variables are expressed as means (standard deviation) while for categorical variables  as count and (% percentages). *ANOVA test or Pearson χ2 test as appropriate. Table 3. Binary logistic regression model identifying risk  factors for new UTI episodes at 12 months after HA and CS  treatment  Variables OR p  value IC (95%) Age: 10 years more (from 20  to 80) 1.14 0.327 0.87-1.44 Age   ≥ 50 years 3.41 0.003 1.51-7.71 UTI per year ( ≥ 4 episodes) 3.31 0.003 1.51-7.22 Elevated BMI status (&gt;25) 1.21 0.598 0.5-2.5 Constipation  1.1 0.792 0.51-2.40 UTI: urinary tract infection; HA: hyaluronic acid; CS: chondroitin sulphate; BMI: body mass  index. </p>
                                        
                                            <p>1. CUAJ • September-October 2014 • Volume 8, Issues 9-10 © 2014 Canadian Urological Association Antonio Cicione, MD; *  Francesco  Cantiello, MD; *  Giuseppe Ucciero, MD; *  Andrea Salonia, MD; †  Marco Torella, MD; §  Marco De Sio, MD; ¥  Riccardo Autorino, MD; ¥  Antonio Carbone, MD; £  Martin Romancik, MD; #  Roman Tomaskin, MD; ±  Rocco Damiano, MD * * Department of Urology &amp; Research Doctorate Urology Program, Magna Graecia University, Catanzaro, Italy;  † Department of Urology, University Vita-Salute San Raffaele, Milano, Italy;  § Gynaecology Unit,  Second University of Naples, Napoli, Italy;  ¥ Urology Unit, Second University of Naples, Napoli, Italy;  £ Unit of Urology – ICOT, Sapienza University of Rome, Latina, Italy;  # Department of Urology, St. Cyril  and Method University Hospital, Bratislava, Slovakia;  ± Department of Urology, Faculty Hospital of Martin (MFN), Martin, Slovakia Cite as:  Can Urol Assoc J  2014;8(9-10):e721-7.  http://dx.doi.org/10.5489/cuaj.1989 Published online October 22, 2014. Abstract  Introduction:  We assess the effectiveness of intravesical instilla - tion of hyaluronic acid (HA) and chondroitin sulphate (CS) as a  non-antibiotic treatment option for prophylaxis of recurrent urinary  tract infections (UTIs) in female patients. Methods:  This  was  a  retrospective  cohort  study  involving  7  European institutions. We included patients with recurrent UTIs  who received intravesical instillations of Ialuril (IBSA International) (50   mL HA 1.6% and CS 2% solution) between January 2010 and  March 2012. Medication schedule, length of follow-up, recurrence  infection time, number of UTIs/patients/year, patient quality of life,  subjective symptoms score, and treatment-emergent side effects  were recorded and analyzed. Results : In total, 157 women (mean age: 54.2   ±   4.1   years) were  included in the analysis. All patients had at least 12   months follow- up. After 4 weekly and 5 monthly HA-CS bladder instillations, UTI  episodes decreased from 4.13   ±   1.14 to 0.44   ±   0.50 ( p  =   0.01)   at 12  months, while recurrent UTI time prolonged from 94.8   ±   25.1   days  to 178.4   ±   37.3   days ( p   =   0.01)   at 12 months. An improvement  in symptoms and quality of life was achieved. A medium-depth  pain after medication instillation was the most reported side effect.  Regression model analysis showed significant risk factors in devel - oping new UTI episodes: being more than 50 years old and having  more than 4 UTI episodes per year (OR 3.41; CI 95%; 1.51-7.71,  p   =   0.003 and OR 3.31; CI 95% 1.51-7.22;  p   =   0.003, respec - tively). Retrospective design and lack of a control group represent  two main limitations of the study. Conclusions:  Restoring glycosaminoglycans bladder layer therapy  is a promising non-antibiotic therapy to prevent recurrent UTIs. Introduction  According to the European Association of Urology (EAU)  guidelines,  recurrent  urinary  tract  infections  (UTIs)  are  defined as the presence of lower urinary tract symptoms  and at least 3 episodes of documented positive urine culture  &gt;10 3  colonies/mL on a voided urine volume specimen in  the previous 12 months. 1 Uncomplicated recurrent UTIs are extremely common. 2   Among healthy young women, urinary infections recur in  25% of cases within 6 months after the first UTI. 3  Recurrent  UTIs are experienced by as many as 5% of women at some  time during their life, with an increasing recurrence rate in  women with more than 1 prior UTI. 4 Antibiotics are routinely prescribed for UTI, with the pri - mary goal being a rapid resolution of urinary symptoms. An  antimicrobial prophylaxis given for 6 consecutive months is  suggested by the EAU Guidelines as a therapeutic option for  women with recurrent UTIs when behavioural modifications  and non-antimicrobial measures, such as cranberry juice or  probiotics, are unsuccessful. 1 According to a Cochrane systematic review, 5  continuous  low-dose antimicrobial prophylaxis is effective in preventing  UTIs, with a 0.15   risk ratio (RR) for clinical recurrence per  patient per year. However, continuous low-dose antimicro - bial prophylaxis also presents a 1.58   RR for severe treatment- emergent side effects, such as vaginal/oral candidiasis and  gastrointestinal symptoms; these symptoms eventually lead  to treatment withdrawal. Furthermore, patients with history  of recurrent UTIs have a higher incidence of sexual pain,  secondary provoked vestibulodynia, 6  and irritative urinary  symptoms even when they are infection-free. 7 Research in the field of glycosaminoglycans (GAGs) start - ed in 1970, 8  but only recently has there been an increasing  Intravesical treatment with highly-concentrated hyaluronic acid  and chondroitin sulphate in patients with recurrent urinary tract  infections: Results from a multicentre survey original research E721 </p>
                                        
                                            <p>3. CUAJ • September-October 2014 • Volume 8, Issues 9-10 E723 i ntravesical  gag s treatment in patients with recurrent UT i s Statistical analysis  Normal distribution of continuous variables was initially  tested by Kurtosi test. Mean and standard deviation (SD)  were used for descriptive statistics. The statistical signifi - cance of differences in means and proportions was tested  with the 2-tailed  t   test and the Pearson  χ 2  test, respectively.  Kaplan Meier method tested time to UTI recurrence, con - sidering a 12-month time frame before and after treatment.  Binary logistic regression analyses tested the effect of various  independent variables on UTI development. All statistical  analyses were performed using SPSS 18.0 for windows (SPSS  Inc., IBM Corp., Somers, NY). All tests were two-sided, with  a significance level set at 0.05. Results  Study sample and intervention  Overall, 157 patients were included in the study (Table 1).  A course of 4 instillations over 4 consecutive weeks (induc - tion phase) followed by 5 monthly instillations (maintenance  phase) was the main HA-CS treatment schedule, although  36 (28%) patients received a different regimen due to further  instillations up to 12 months. Delaying instillations for posi - tive urine culture was needed in 23 cases (14.6 %) . Pre-treatment assessment  Mean total PUF and symptom score were 20.09 (5.7) and  13.7 (3.78), respectively, whereas the mean QoL SF-36 score  was 59.25 (11.1). At cystoscopy, a bladder hyperemia was  reported in 74 patients (47.1%). Follow-up  A 12-month follow-up was available for all patients, with  41 patients (26.1%) having a longer (24 months) follow-up.  Outcome assessment  At  12  months,  few  patients  have  had  new  UTIs,  but  an  increasing trend in UTIs was recorded at 24 months, with  41 patients reporting up to 139 UTIs episodes. E. Coli rep - resented the most frequent uropathogen, mainly requiring  a 3-day course of quinolones. The estimating time-to-UTI recurrence at the 12-month  follow-up  was  longer  compared  with  the  pre-treatment  value: 178.4 (37.3) versus 94.8 (25.1) days ( p   =   0.01) (Fig.  1). Similarly, the computed number of UTIs was lower than  before treatment: 0.44 (0.50) versus 4.13 (1.14) episodes/ person/year ( p   =   0.01). A  significant  improvement  in  the  PUF  and  the  SF-36  scores during the first 12 months (Table 2, Fig. 2) was noted,  with a subsequent worsening of symptoms or QoL, respec - tively, over the subsequent 12 months. Overall, 10 patients reported moderate storage urinary  symptoms in the absence of infection, but only 1 required  medication for symptom relief. Patients reported moderate  pain for 2 days after both weekly (mean visual analogue  scale [VAS] 4.5) and monthly (mean VAS 4.2) instillations.   At logistic regression analysis, the following factors were  predictors of new UTI episodes: age over 50 (odds ratio [OR]  3.41; 95% confidence interval [CI] 1.51-7. 71;  p   =   0.003)  and having more than 4 UTI episodes per year (OR 3.31;  95% CI, 1.51-7.22;  p  =   0.003) (Table 3). Table 1. Individual patient characteristics  (A) Mean (SD) No. (%) Patients, no.  157 Age, yr 53.1 (13.4) BMI, kg/m2 25.1 (3.4) Affected with constipation  73 (46.4) Menopausal stage 71 (45.2) Follow-up length 12 months  157 (B) UTI episodes over last year,  4.13 (1.14) UTI recurrence time over last year,  days 94.8 (25.1) UTI agent, E. coli/other   133  (84.7)/24  (15.3) Advised medication, quinolone/ other  136  (86.6)/21  (13.4) 3-day void urine diary 16.3 (4.6) Qmax, mL/sec 24.05 (4.6) Qave, mL/sec 12.0 (3.2) PVR, mL 18.8 (16.4) Bladder mucosa hyperemia at  cystoscopy1 74 (47.1) Total PUF score 20.09 (5.7) Symptom score 13.7 (3.78) QoL SF-36 score 59.25  (11.1) (C) Instillations schedule, 4 weekly +   5 monthly/different 121 (77)/36  (23) One or more additional  instillations 36 (23) Regimen weekly/biweekly  29/7    Delayed instillations due to urine  culture positivity status, no. cases 23 (14.6) BMI; body mass index; UTI: urinary tract infection; PVR: post-void residual volume; PUF:  pelvic pain and urinary/frequency patient symptom scale; QoL: quality of life; SD: standard  deviation. Data of continuous variables are expressed as means (standard deviation) while  for categorical variables as count and (% percentages). 1Defined as: bladder mucosa area  reddened despite the close mucosa. </p>
                                        
                                            <p>6. interface for host-pathogen interaction, as well as a co- receptor for bacteria. Rouschop and colleagues 28  showed  that E. Coli invades host cells binding cellular surface HA,  and then by CD44-HA interaction. CD44 is a family of type  I transmembrane glycoproteins with a wide tissue distri - bution implicated in many physiological and pathological  processes, thus including cytokines/chemokines secretion  in the urothelium itself.   Therefore, it appears reasonable to  speculate that intravesical GAGs instillations may act as a  competitive “bacterial glue.” The key GAGs role in protecting from bacterial rUTIs  also lies in the potential gradual growing of antimicrobial  resistance and the potential side effects of long antibiotic  prophylaxis. Until the late 1990s, E. Coli was relatively sus - ceptible to first-line antibiotics, including cephalosporins,  fluoroquinolones and trimethoprim-sulfamethoxazole. More  recently, several surveillance studies have shown an increas - ing resistance rate (between 20% and 45%) toward those  medications. 29  Furthermore, prolonged antibiotic use as a  prophylactic approach toward recurrent UTIs is eventually  burdened by a greater risk of side effects, such as vaginal and  oral candidiasis and gastrointestinal symptoms. 5  Therefore,  novel non-antibiotic prophylaxis therapies would be desir - able. Cranberry and probiotics are the further non-antibiotic  measures available for recurrent UTIs prophylaxis with low  efficacy evidence. 1   Our study has its limitations, including its retrospective  design and lack of a control group. However, participat - ing centres adopted a similar treatment protocol, including  a comparable follow-up schedule. We included a security  profile for GAGs therapy in a larger sample than in pre - vious studies. 14-17  Moreover, we included a representative  image of recurrent UTIs in clinical practice. Furthermore,  we described the real-life disease impact on patient QoL.    During past years the management of recurrent UTIs in  the field of urothelium GAGs has continuously evolved. 30  It  would seem reasonable to gather more knowledge of GAGs’  role over infections.  Conclusion  This study suggests that intravesical HA-CS administration  is an effective and well-tolerated non-antibiotic treatment  option in women with recurrent UTI.  Competing interests:  Dr. Cicione, Dr. Cantiello, Dr. Ucciero, Dr. Salonia, Dr. Torella, Dr. De Sio,  Dr. Autorino, Dr. Carbone, Dr. Romancik, Dr. Tomaskin and Dr. Damiano all declare no competing  financial or personal interests. This paper has been peer-reviewed.  References 1.   Grabe M, Bjerklund-Johansen TE, Botto H, et al. European Urological Association. Guidelines on Urological  Infections; 2013.  http://www.uroweb.org/gls/pdf/19%20Urological%20infections_LR.pdf . Accessed  October 14, 2014. 2.   Wagenlehner FM, Weidner W, Naber KG. An update on uncomplicated urinary tract infections in women.  Curr Opin Urol  2009;19:368-74. http://dx.doi.org/10.1097/MOU.0b013e32832ae18c 3.   Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among col - lege women.  Am J Epidemiol  2000;151:1194-205. http://dx.doi.org/10.1093/oxfordjournals.aje. a010170 4.   Czaja CA, Stamm WE, Stapleton AE, et al. Prospective cohort study of microbial and inflammatory  events immediately preceding Escherichia coli recurrent urinary tract infection in women.  J Infect Dis   2009;;200:528-36. http://dx.doi.org/10.1086/600385 5.   Albert X, Huertas I, Pereiro II, et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant  women.  Cochrane Database Syst Rev  2004;CD001209. 6.   Arnold LD, Bachmann GA, Rosen R, et al. Assessment of vulvodynia symptoms in a sample of US women:  A prevalence survey with a nested case control study.  Am J Obstet Gynecol  2007;196:128-6. http:// dx.doi.org/10.1016/j.ajog.2006.07.047 7.   Arya LA, Northington GM, Asfaw T, et al. Evidence of bladder oversensitivity in the absence of an infection  in premenopausal women with a history of recurrent urinary tract infections.  BJU Int  2012;110:247-51.  http://dx.doi.org/10.1111/j.1464-410X.2011.10766.x 8.   Esko JD, Kimata K, Lindahl U. Proteoglycans and Sulfated Glycosaminoglycans. In: Varki A, Cummings  RD, Esko JD, et al., editors.  Essentials of Glycobiology . 2nd edition. Cold Spring Harbor (NY): Cold Spring  Harbor Laboratory Press; 2009. Chapter 16. Available from:  http://www.ncbi.nlm.nih.gov/books/ NBK1900/ . Accessed October 14, 2014. 9.   Damiano R, Cicione A. The role of sodium hyaluronate and sodium chondroitin sulphate in the management  of bladder disease.  Ther Adv Urol  2011;3:223-32. http://dx.doi.org/10.1177/1756287211418723 10.   Parsons CL, Greenspan C, Mulholland SG. The primary antibacterial defense mechanism of the bladder.  Invest Urol  1975;13:72-8. 11.   Parsons CL. New concepts in interstitial cystitis.  Int Urogynecol J Pelvic Floor Dysfunct  1997;8:1-2. http:// dx.doi.org/10.1007/BF01920285 12.   Lazzeri M, Montorsi F. The therapeutic challenge of “chronic cystitis:” search well, work together, and  gain results.  Eur Urol  2011;60:78-80. http://dx.doi.org/10.1016/j.eururo.2011.03.039 13.   Costantini E, Lazzeri M, Pistolesi D, et al. Morphological changes of bladder mucosa in patients who  underwent instillation with combined sodium hyaluronic acid-chondroitin sulphate (Ialuril).  Urol Int   2013;91:81-8. http://dx.doi.org/10.1159/000345047 14.   De Vita D, Giordano S. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacte - rial cystitis: A randomized study.  Int Urogynecol J  2012;23:1707-13. http://dx.doi.org/10.1007/ s00192-012-1794-z 15.   Lipovac M, Kurz C, Reithmayr F, et al. Prevention of recurrent bacterial urinary tract infections by intravesical  instillation of hyaluronic acid.  Int J Gynaecol Obstet  2007;96:192-5. http://dx.doi.org/10.1016/j. ijgo.2006.11.025 16.   Constantinides C, Manousakas T, Nikolopoulos P, et al. Prevention of recurrent bacterial cystitis by  intravesical administration of hyaluronic acid: A pilot study.  BJU Int  2004;93:1262-6. http://dx.doi. org/10.1111/j.1464-410X.2004.04850.x 17.   Damiano R, Quarto G, Bava I, et al. Prevention of recurrent urinary tract infections by intravesical admin - istration of hyaluronic acid and chondroitin sulphate: A placebo-controlled randomised trial.  Eur Urol   2011;59:645-51. http://dx.doi.org/10.1016/j.eururo.2010.12.039 18.   Parsons CL, Dell J, Stanford EJ, et al. Increased prevalence of interstitial cystitis: Previously unrecognized  urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium  sensitivity.  Urology  2002;60:573-8. http://dx.doi.org/10.1016/S0090-4295(02)01829-0 19.   The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).  http://www2.niddk.nih. gov/ . Accessed October 14, 2014. 20.   Birder LA, de Groat WC. Mechanisms of disease: Involvement of the urothelium in bladder dysfunction.  Nat Clin Pract Urol  2007;4:46-54. http://dx.doi.org/10.1038/ncpuro0672 21.   Parsons CL. The therapeutic role of sulfated polysaccharides in the urinary bladder.  Urol Clin North Am  1994;21:93-100. 22.   Foxman B, Brown P. Epidemiology of urinary tract infections: Transmission and risk factors, inci - dence, and costs.  Infect Dis Clin North Am  2003;17:227-41. http://dx.doi.org/10.1016/S0891- 5520(03)00005-9 23.   Nicolle LE. Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis.  Urol Clin  North Am  2008;35:1-12, v. http://dx.doi.org/10.1016/j.ucl.2007.09.004 CUAJ • September-October 2014 • Volume 8, Issues 9-10 E726 c icione et al. </p>
                                        
                                            <p></p>
                                        
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="statistic" slide-url="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html">
                                    <div class="row">
                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Nézetek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1387</span>
                                                    <i class="fa fa-play"></i> Total Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1042</span>
                                                    <i class="fa fa-circle-o"></i> Website Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">345</span>
                                                    <i class="fa fa-code"></i> Embedded Views
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Műveletek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="total-share">0</span>
                                                    <i class="fa fa-share-alt"></i> Social Shares
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-up"></i> Likes
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-down"></i> Nemkedvelések
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-comments-o"></i> Comments
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Share count</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="facebook-badge">0</span>
                                                    <i class="fa fa-facebook-square"></i> Facebook
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="twitter-badge">0</span>
                                                    <i class="fa fa-twitter-square"></i> Twitter
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="linkedin-badge">0</span>
                                                    <i class="fa fa-linkedin-square"></i> LinkedIn
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="google-badge">0</span>
                                                    <i class="fa fa-google-plus-square"></i> Google+
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                    <div class="row">
                                        <div class="col-lg-12">
                                            <h4 class="mt0"> Embeds
                                                <span class="badge badge-pill float-right">
                                                    3
                                                </span>
                                            </h4>
                                            <ul class="list-group" style="height: 150px;overflow: auto;">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">23</span>
                                                    hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">15</span>
                                                    www.hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">2</span>
                                                    odoo.hbs.hu
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="col-xl-4 col-lg-4 col-md-12 col-12">
                    <ul class="nav nav-tabs" role="tablist">
                        <li class="nav-item"><a aria-controls="related" href="#related" class="nav-link active" data-toggle="tab">Kapcsolódó</a></li>
                        <li class="nav-item"><a aria-controls="most_viewed" href="#most_viewed" class="nav-link" data-toggle="tab">Most Viewed</a></li>
                    </ul>
                    <div class="tab-content">
                        <div role="tabpanel" id="related" class="tab-pane active mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/19/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html"><h6 class="mb-1">Cikk a Neurourology and Urodynamics-ban 2018.</h6></a>
            <small class="text-muted">
                1472 Views . <timeago class="timeago" datetime="2019-10-31 13:28:23.618732"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-diagnostic-algorhytm-21.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/21/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-diagnostic-algorhytm-21.html"><h6 class="mb-1">IC-BPS diagnostic algorhytm.</h6></a>
            <small class="text-muted">
                1487 Views . <timeago class="timeago" datetime="2019-10-31 13:29:57.450898"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="glycosaminoglycan-therapy-for-bladder-diseases-22.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/22/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="glycosaminoglycan-therapy-for-bladder-diseases-22.html"><h6 class="mb-1">Glycosaminoglycan Therapy for Bladder Diseases</h6></a>
            <small class="text-muted">
                1384 Views . <timeago class="timeago" datetime="2019-10-31 13:30:10.980936"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="essic-2017-budapest-abstracts-23.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/23/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="essic-2017-budapest-abstracts-23.html"><h6 class="mb-1">ESSIC 2017 Budapest abstracts</h6></a>
            <small class="text-muted">
                1463 Views . <timeago class="timeago" datetime="2019-10-31 13:30:38.129948"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/24/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html"><h6 class="mb-1">Prevalence of Symptoms of Bladder Pain Syndrome 2011</h6></a>
            <small class="text-muted">
                1303 Views . <timeago class="timeago" datetime="2019-10-31 13:30:57.131521"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/25/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html"><h6 class="mb-1">The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. 2017</h6></a>
            <small class="text-muted">
                1361 Views . <timeago class="timeago" datetime="2019-10-31 13:35:55.689470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/26/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html"><h6 class="mb-1">Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. 2016</h6></a>
            <small class="text-muted">
                1298 Views . <timeago class="timeago" datetime="2019-10-31 13:36:14.959707"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/27/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html"><h6 class="mb-1">PENTOSAN POLYSULFATE SODIUM FOR THERAPY of IC Urology 1990</h6></a>
            <small class="text-muted">
                1413 Views . <timeago class="timeago" datetime="2019-10-31 13:37:27.415502"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/28/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html"><h6 class="mb-1">Interstitial cystitis intravesical therapy tau-06-S2-S171 2017</h6></a>
            <small class="text-muted">
                1367 Views . <timeago class="timeago" datetime="2019-10-31 13:38:04.204366"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/29/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html"><h6 class="mb-1">Novel targeted bladder drug-delivery systems rru-7-169 2015</h6></a>
            <small class="text-muted">
                1488 Views . <timeago class="timeago" datetime="2019-10-31 13:38:18.425299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/30/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections 2016 bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1220 Views . <timeago class="timeago" datetime="2019-10-31 13:38:52.835202"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/32/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html"><h6 class="mb-1">IC_BPS and glycosaminoglycans replacement therapy 2015 tau-04-06-638</h6></a>
            <small class="text-muted">
                1249 Views . <timeago class="timeago" datetime="2019-10-31 13:39:22.993300"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/33/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html"><h6 class="mb-1">Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans- an update on the evidence 2016 Urology</h6></a>
            <small class="text-muted">
                1387 Views . <timeago class="timeago" datetime="2019-10-31 13:40:52.836690"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/34/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html"><h6 class="mb-1">Hyaluronic Acid and Its Composites as a Local Antimicrobial-Antiadhesive Barrier 2017.jbjiv02p0063</h6></a>
            <small class="text-muted">
                1309 Views . <timeago class="timeago" datetime="2019-10-31 13:45:41.648470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/35/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html"><h6 class="mb-1">Evidence-based criteria for the pain of IC_BPS in women 2008 nihms43157</h6></a>
            <small class="text-muted">
                1299 Views . <timeago class="timeago" datetime="2019-10-31 13:45:59.326213"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/36/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html"><h6 class="mb-1">Intravesical Glycosaminoglycan Replacement with Chondroitin_2015_Article_306</h6></a>
            <small class="text-muted">
                1357 Views . <timeago class="timeago" datetime="2019-10-31 13:46:19.773972"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulphate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-bmjopen-2015-009669-37.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/37/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulphate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-bmjopen-2015-009669-37.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulphate (CS) for the treatment of female recurrent urinary tract infections- bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1239 Views . <timeago class="timeago" datetime="2019-10-31 13:46:36.042595"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                        <div role="tabpanel" id="most_viewed" class="tab-pane  mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="sugarvedo-ruhazat-ismerteto-3.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/3/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="sugarvedo-ruhazat-ismerteto-3.html"><h6 class="mb-1">Sugárvédő ruházat ismertető</h6></a>
            <small class="text-muted">
                3284 Views . <timeago class="timeago" datetime="2018-10-20 14:31:25.547995"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="op-set-system-5.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/5/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="op-set-system-5.html"><h6 class="mb-1">OP Set System</h6></a>
            <small class="text-muted">
                3044 Views . <timeago class="timeago" datetime="2018-11-16 13:38:03.543744"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kompresszios-polya-felhelyezese-8.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/8/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kompresszios-polya-felhelyezese-8.html"><h6 class="mb-1">Kompressziós pólya felhelyezése</h6></a>
            <small class="text-muted">
                2846 Views . <timeago class="timeago" datetime="2018-11-16 13:39:25.884480"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kotszer-polya-l-r-6.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/6/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kotszer-polya-l-r-6.html"><h6 class="mb-1">Kötszer Pólya L&amp;R</h6></a>
            <small class="text-muted">
                2643 Views . <timeago class="timeago" datetime="2018-11-16 13:38:35.611223"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="nedves-sebkezeles-flyer-l-r-7.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/7/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="nedves-sebkezeles-flyer-l-r-7.html"><h6 class="mb-1">Nedves sebkezelés flyer L&amp;R</h6></a>
            <small class="text-muted">
                2438 Views . <timeago class="timeago" datetime="2018-11-16 13:38:59.835920"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-liner-10.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/10/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-liner-10.html"><h6 class="mb-1">PDB_Actico UlcerSys Liner</h6></a>
            <small class="text-muted">
                2324 Views . <timeago class="timeago" datetime="2018-11-16 13:39:54.728282"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-2.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/2/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-2.html"><h6 class="mb-1">SciCan STATIM G4</h6></a>
            <small class="text-muted">
                2321 Views . <timeago class="timeago" datetime="2018-10-20 14:10:02.671163"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-9.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/9/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-9.html"><h6 class="mb-1">PDB_Actico UlcerSys</h6></a>
            <small class="text-muted">
                2209 Views . <timeago class="timeago" datetime="2018-11-16 13:39:42.488113"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-hasznalati-utmutato-v1-1-12.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/12/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-hasznalati-utmutato-v1-1-12.html"><h6 class="mb-1">UroStill_hasznalati_utmutato_v1.1</h6></a>
            <small class="text-muted">
                2038 Views . <timeago class="timeago" datetime="2019-10-31 13:22:24.531510"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="koronavirus-jarvany-61.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/61/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="koronavirus-jarvany-61.html"><h6 class="mb-1">KORONAVIRUS JARVANY</h6></a>
            <small class="text-muted">
                1773 Views . <timeago class="timeago" datetime="2020-04-09 15:16:22.317496"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-1.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/1/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-1.html"><h6 class="mb-1">SciCan Statim G4</h6></a>
            <small class="text-muted">
                1708 Views . <timeago class="timeago" datetime="2018-10-20 14:09:31.661802"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="new-aiding-device-for-self-instillation-v2-16.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/16/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="new-aiding-device-for-self-instillation-v2-16.html"><h6 class="mb-1">New_aiding_device_for_self-instillation_v2</h6></a>
            <small class="text-muted">
                1690 Views . <timeago class="timeago" datetime="2019-10-31 13:23:48.863175"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kitpack-11.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/11/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="kitpack-11.html"><h6 class="mb-1">Kitpack</h6></a>
            <small class="text-muted">
                1684 Views . <timeago class="timeago" datetime="2018-11-16 14:52:39.736537"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="icbps-szoszedet-14.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/14/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="icbps-szoszedet-14.html"><h6 class="mb-1">ICBPS_SZÓSZEDET</h6></a>
            <small class="text-muted">
                1618 Views . <timeago class="timeago" datetime="2019-10-31 13:23:06.826135"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/15/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html"><h6 class="mb-1">IC - FAQ-s and appropriate answers Mumbai 2019</h6></a>
            <small class="text-muted">
                1612 Views . <timeago class="timeago" datetime="2019-10-31 13:23:19.219912"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-users-manual-v1-1-13.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/13/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-users-manual-v1-1-13.html"><h6 class="mb-1">UroStill_Users_Manual_v1.1</h6></a>
            <small class="text-muted">
                1605 Views . <timeago class="timeago" datetime="2019-10-31 13:22:47.677753"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="l-r-corporate-film-4.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/4/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="l-r-corporate-film-4.html"><h6 class="mb-1">L&amp;R Corporate Film</h6></a>
            <small class="text-muted">
                1601 Views . <timeago class="timeago" datetime="2018-11-14 15:53:51.760680"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    
                </main>
                <footer class="bg-light o_footer">
                    <div id="footer" class="oe_structure oe_structure_solo">
      <section class="s_text_block pb8 pt40">
        <div class="container">
          <div class="row" style="border-top: solid 1px #ddd; padding-top: 30px;">
            <div class="col-lg-4">
              <h5>További tartalmak</h5>
              <ul class="list-unstyled">
                <li>
                  <a href="../../blog/hirek-esemenyek-1.html" data-original-title="" title="" aria-describedby="tooltip310735">Blog</a>
                  <br/>
                  <a href="../../adatkezelesi-tajekoztato.html">Adatkezelési tájékoztató</a>
                </li>
                <li>
                  <br/>
                </li>
              </ul>
            </div>
            <div class="col-lg-4" id="connect">
              <h5>Elérhetőségek</h5>
              <ul class="list-unstyled">
                <li>
                  <i class="fa fa-phone"></i>
                  <span data-note-id="2">+36 1 452 1700</span>
                </li>
                <li>
                  <i class="fa fa-envelope"></i>
                  <span><a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="30595e565f705852431e5845">[email&#160;protected]</a></span>
                </li>
              </ul>
              <p> </p>
            </div>
            <div class="col-lg-4">
              <h5>
                <span>HBS Medical</span>
                <small> – <a href="../../aboutus.html" data-original-title="" title="" aria-describedby="tooltip425138">Kapcsolat</a></small>
              </h5>
              <p>&nbsp;<br/></p>
            </div>
          </div>
        </div>
      </section>
    </div>
  <div class="o_footer_copyright">
            <div class="container">
                <div class="row">
                    <div class="col-lg-6 text-muted text-center text-md-left">
                        <span>Copyright &copy;</span> <span itemprop="name">HBS Medical</span>
                        
    

                    </div>
                    <div class="col-lg-6 text-right o_not_editable">
                        
    <!--<div class="o_brand_promotion text-muted">
        Az oldalt készítette:
        <a href="https://eyssen.hu/" target="_blank"><img src="../../web/image/606/eyssen_logo_blue.png" width="120"/></a>
    </div>-->

                    </div>
                </div>
            </div>
        </div>
    </footer>
            </div>
        <script data-cfasync="false" src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script id="tracking_code">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

            ga('create', _.str.trim('UA-52898474-1'), 'auto');
            ga('send','pageview');
        </script>
    
        
            </body>
        
<!-- Mirrored from hbs.hu/slides/slide/intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:04:14 GMT -->
</html>
    
    
